Clinical Trial Update: Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma [Phase 1]

View source ↗

Summary

This entry describes a Phase 1 clinical trial of a genetically engineered HSV-1 therapy for recurrent malignant glioma, including glioblastoma, anaplastic astro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Genetically Engineered HSV-1

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-02-02